drugset
drugset / Trial / NCT04169399

Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT

NCT04169399 ↗

Phase 2 Unknown 30 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of toripalimab plus stereotactic body radiotherapy for hepatocellular carcinom with portal vein tumor thrombus.

Timeline

Start
2019-11-17
Primary completion
2020-11-17
Completion
2021-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

hepatocellular carcinoma